Delta: HealthTech Innovators Tiny Titans: Exploring the Transformative Impact of Nanobots in Modern Medicine
Cancer, one of the most lethal diseases of the twenty-first century, continues to challenge the medical community. Conventional treatments like chemotherapy and radiation can be effective, but they often come with many side effects
Now Imagine tiny robots, meticulously designed, capable of targeting cancer cells at their very core – the DNA. These nanobots offer a level of precision in treatment that traditional methods can't match, potentially reducing the need for harsh chemotherapy and radiation. This is not a dream, but it is true due to companies like DNA Nanobots.
However, the potential of DNA nanobots extends far beyond the treatment of cancer. They could be engineered to detect specific molecules or markers associated with various diseases, leading to earlier and more accurate diagnoses. Today we talk to Chris Lucas, the Chief Science Officer of DNA Nanobots. With a deep-seated background in technology commercialization and DNA nanotechnology, Chris is not just riding the wave of innovation – he's helping to create it.
Join us today on Delta, as we dive into the exciting and rapidly evolving world of DNA Nanobots.
This Episode is brought to you by MeshAI
MeshAI is a scheduling software for healthcare workers, including medical students, residents, physicians, and nurses, it alleviates administrative burdens by leveraging AI algorithms for scheduling shifts.
MeshAI automates the creation of equitable schedules, efficiently assigns the most suitable staff for each shift, and facilitates easy shift trading among healthcare professionals.
MeshAI is more than just a scheduling tool; it's specifically designed to cater to the unique training requirements of each residency program.
Time stamps:
00:00 - Introduction
02:00 - What are DNA Nanobots, how do they work, and where is the technology currently?
05:24 - Applications of DNA Nanobots technology.
07:59 - Personal journey into the DNA Nanobots space and the motivation for starting the company.
24:55 - DNA Nanobots' distinctiveness in the crowded field of nanotechnology in medicine.
29:48 - The role of artificial intelligence in enhancing DNA Nanobots technology and its development.
34:51 - Current treatments approved using DNA Nanobots technology.
36:23 - Approach to FDA approval and challenges in regulatory compliance for medical technologies.
37:33 - Challenges in innovating within the biotech space.
48:39 - Personal motivation and ultimate goals for DNA Nanobots.
Find us on YouTube: https://youtu.be/ChYP7muspic
Roupen Odabashian:
LinkedIn: https://www.linkedin.com/in/roupen-odabashian-183aaa142/ X: https://twitter.com/RoupenMD
For sponsorships please Email: roupen@deltahealth.tech
Christopher Lucas, Ph.D.
LinkedIn: https://www.linkedin.com/in/chrislucasdnananobots/
DNANanobots website: